{"id":"https://openalex.org/W1490907820","doi":"https://doi.org/10.1111/j.1365-2141.2010.08315.x","title":"Phase I trial of bortezomib in combination with rituximab\u2010HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma","display_name":"Phase I trial of bortezomib in combination with rituximab\u2010HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma","publication_year":2010,"publication_date":"2010-08-05","ids":{"openalex":"https://openalex.org/W1490907820","doi":"https://doi.org/10.1111/j.1365-2141.2010.08315.x","mag":"1490907820","pmid":"https://pubmed.ncbi.nlm.nih.gov/20735402"},"language":"en","primary_location":{"id":"doi:10.1111/j.1365-2141.2010.08315.x","doi":"https://doi.org/10.1111/j.1365-2141.2010.08315.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2141.2010.08315.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2141.2010.08315.x","source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2141.2010.08315.x","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5089736242","display_name":"Jorge Enrique Romaguera","orcid":"https://orcid.org/0000-0003-4830-9173","observed_orcids":["https://orcid.org/0000-0003-4830-9173"]},"institutions":[{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]},{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jorge E. Romaguera","raw_affiliation_strings":["Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd. #429, Houston, TX 77030, USA. jromague@mdanderson.org","Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd. #429, Houston, TX 77030, USA. jromague@mdanderson.org","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","institution_ids":["https://openalex.org/I1324520350"]},{"raw_affiliation_string":"Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028677309","display_name":"Luis Fayad","orcid":"https://orcid.org/0000-0002-1844-5548","observed_orcids":["https://orcid.org/0000-0002-1844-5548"]},"institutions":[{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]},{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Luis E. Fayad","raw_affiliation_strings":["Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","institution_ids":["https://openalex.org/I1324520350"]},{"raw_affiliation_string":"Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034301588","display_name":"Peter Joseph McLaughlin","orcid":"https://orcid.org/0000-0002-8011-642X","observed_orcids":["https://orcid.org/0000-0002-8011-642X"]},"institutions":[{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]},{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter McLaughlin","raw_affiliation_strings":["Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","institution_ids":["https://openalex.org/I1324520350"]},{"raw_affiliation_string":"Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011181925","display_name":"Barbara Pro","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]},{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Barbara Pro","raw_affiliation_strings":["Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","institution_ids":["https://openalex.org/I1324520350"]},{"raw_affiliation_string":"Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Alma Rodriguez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]},{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alma Rodriguez","raw_affiliation_strings":["Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","institution_ids":["https://openalex.org/I1324520350"]},{"raw_affiliation_string":"Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100438316","display_name":"Michael L. Wang","orcid":"https://orcid.org/0000-0001-9748-5486","observed_orcids":["https://orcid.org/0000-0001-9748-5486"]},"institutions":[{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]},{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Wang","raw_affiliation_strings":["Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","institution_ids":["https://openalex.org/I1324520350"]},{"raw_affiliation_string":"Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018180359","display_name":"Pamela Weaver","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]},{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pamela Weaver","raw_affiliation_strings":["Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","institution_ids":["https://openalex.org/I1324520350"]},{"raw_affiliation_string":"Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035744899","display_name":"Kimberly Hartig","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]},{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kimberly Hartig","raw_affiliation_strings":["Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","institution_ids":["https://openalex.org/I1324520350"]},{"raw_affiliation_string":"Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074743570","display_name":"Larry W. Kwak","orcid":"https://orcid.org/0000-0002-1884-5349","observed_orcids":["https://orcid.org/0000-0002-1884-5349"]},"institutions":[{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]},{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Larry W. Kwak","raw_affiliation_strings":["Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","institution_ids":["https://openalex.org/I1324520350"]},{"raw_affiliation_string":"Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013717203","display_name":"Tatyana A. Feldman","orcid":"https://orcid.org/0000-0002-4458-2896","observed_orcids":["https://orcid.org/0000-0002-4458-2896"]},"institutions":[{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]},{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tatyana Feldman","raw_affiliation_strings":["Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","institution_ids":["https://openalex.org/I1324520350"]},{"raw_affiliation_string":"Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103417804","display_name":"J. W. G. Smith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]},{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Judy Smith","raw_affiliation_strings":["Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","institution_ids":["https://openalex.org/I1324520350"]},{"raw_affiliation_string":"Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025128895","display_name":"Peggy Ford","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]},{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peggy Ford","raw_affiliation_strings":["Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","institution_ids":["https://openalex.org/I1324520350"]},{"raw_affiliation_string":"Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046306389","display_name":"Stuart L. Goldberg","orcid":"https://orcid.org/0000-0002-5996-1055","observed_orcids":["https://orcid.org/0000-0002-5996-1055","https://orcid.org/0000-0003-2175-4082"]},"institutions":[{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]},{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stuart Goldberg","raw_affiliation_strings":["Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","institution_ids":["https://openalex.org/I1324520350"]},{"raw_affiliation_string":"Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033513950","display_name":"Andrew L. Pecora","orcid":"https://orcid.org/0000-0002-8368-0632","observed_orcids":["https://orcid.org/0000-0002-8368-0632"]},"institutions":[{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]},{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Pecora","raw_affiliation_strings":["Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","institution_ids":["https://openalex.org/I1324520350"]},{"raw_affiliation_string":"Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5089882481","display_name":"Andre Henri Goy","orcid":"https://orcid.org/0000-0001-5125-6522","observed_orcids":["https://orcid.org/0000-0001-5125-6522"]},"institutions":[{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]},{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andre Goy","raw_affiliation_strings":["Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ, USA","institution_ids":["https://openalex.org/I1324520350"]},{"raw_affiliation_string":"Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5089736242"],"corresponding_institution_ids":["https://openalex.org/I1324520350","https://openalex.org/I1343551460"],"apc_list":{"value":5190,"currency":"USD","value_usd":5190},"apc_paid":null,"fwci":3.2553,"has_fulltext":true,"cited_by_count":48,"citation_normalized_percentile":{"value":0.91324916,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"151","issue":"1","first_page":"47","last_page":"53"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9419999718666077},{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":0.9079999923706055},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.8840000033378601},{"id":"https://openalex.org/keywords/r-hypercvad","display_name":"R-HyperCVAD","score":0.9240000247955322},{"id":"https://openalex.org/keywords/methotrexate","display_name":"methotrexate","score":0.8740000128746033},{"id":"https://openalex.org/keywords/cytarabine","display_name":"cytarabine","score":0.9990000128746033},{"id":"https://openalex.org/keywords/chemoimmunotherapy","display_name":"chemoimmunotherapy","score":0.7870000004768372},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.39800000190734863},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.5709999799728394},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.9430000185966492}],"concepts":[{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.8578044176101685},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8175079822540283},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.7481257319450378},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.6880875825881958},{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.6694205403327942},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5786306858062744},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5782988667488098},{"id":"https://openalex.org/C2779429289","wikidata":"https://www.wikidata.org/wiki/Q408977","display_name":"Vincristine","level":4,"score":0.5035406947135925},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.49432373046875},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.443930447101593},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.3589411973953247},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.34729087352752686},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3350314497947693},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2891058921813965},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.22942057251930237}],"mesh":[{"descriptor_ui":"D000069283","descriptor_name":"Rituximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069283","descriptor_name":"Rituximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069283","descriptor_name":"Rituximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069286","descriptor_name":"Bortezomib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069286","descriptor_name":"Bortezomib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069286","descriptor_name":"Bortezomib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000367","descriptor_name":"Age Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000367","descriptor_name":"Age Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000367","descriptor_name":"Age Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003520","descriptor_name":"Cyclophosphamide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003520","descriptor_name":"Cyclophosphamide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003520","descriptor_name":"Cyclophosphamide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003520","descriptor_name":"Cyclophosphamide","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003520","descriptor_name":"Cyclophosphamide","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003520","descriptor_name":"Cyclophosphamide","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003907","descriptor_name":"Dexamethasone","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003907","descriptor_name":"Dexamethasone","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003907","descriptor_name":"Dexamethasone","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003907","descriptor_name":"Dexamethasone","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003907","descriptor_name":"Dexamethasone","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003907","descriptor_name":"Dexamethasone","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008727","descriptor_name":"Methotrexate","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D008727","descriptor_name":"Methotrexate","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D008727","descriptor_name":"Methotrexate","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D008727","descriptor_name":"Methotrexate","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D008727","descriptor_name":"Methotrexate","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D008727","descriptor_name":"Methotrexate","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014750","descriptor_name":"Vincristine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014750","descriptor_name":"Vincristine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014750","descriptor_name":"Vincristine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014750","descriptor_name":"Vincristine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014750","descriptor_name":"Vincristine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014750","descriptor_name":"Vincristine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D020522","descriptor_name":"Lymphoma, Mantle-Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D020522","descriptor_name":"Lymphoma, Mantle-Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D020522","descriptor_name":"Lymphoma, Mantle-Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D020522","descriptor_name":"Lymphoma, Mantle-Cell","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D020522","descriptor_name":"Lymphoma, Mantle-Cell","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D020522","descriptor_name":"Lymphoma, Mantle-Cell","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D058846","descriptor_name":"Antibodies, Monoclonal, Murine-Derived","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058846","descriptor_name":"Antibodies, Monoclonal, Murine-Derived","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058846","descriptor_name":"Antibodies, Monoclonal, Murine-Derived","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1365-2141.2010.08315.x","doi":"https://doi.org/10.1111/j.1365-2141.2010.08315.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2141.2010.08315.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2141.2010.08315.x","source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},{"id":"pmid:20735402","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20735402","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of haematology","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"doi:10.1111/j.1365-2141.2010.08315.x","doi":"https://doi.org/10.1111/j.1365-2141.2010.08315.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2141.2010.08315.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2141.2010.08315.x","source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.7200000286102295,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320333265","display_name":"Takeda Oncology","ror":"https://ror.org/05vm7p871"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1490907820.pdf","grobid_xml":"https://content.openalex.org/works/W1490907820.grobid-xml"},"referenced_works_count":23,"referenced_works":["https://openalex.org/W1980570693","https://openalex.org/W2001178238","https://openalex.org/W2024691762","https://openalex.org/W2025149232","https://openalex.org/W2029511375","https://openalex.org/W2074610455","https://openalex.org/W2076668534","https://openalex.org/W2078111398","https://openalex.org/W2098134963","https://openalex.org/W2105258029","https://openalex.org/W2117754708","https://openalex.org/W2125684345","https://openalex.org/W2147422161","https://openalex.org/W2154131842","https://openalex.org/W2188767697","https://openalex.org/W2236397427","https://openalex.org/W2551854527","https://openalex.org/W2556085825","https://openalex.org/W2558411656","https://openalex.org/W2561036500","https://openalex.org/W2589187468","https://openalex.org/W2590078033","https://openalex.org/W2994564885"],"related_works":["https://openalex.org/W2802488013","https://openalex.org/W2552081889","https://openalex.org/W4395689019","https://openalex.org/W2759565649","https://openalex.org/W2093055119","https://openalex.org/W2025149232","https://openalex.org/W2607164148","https://openalex.org/W2577306999","https://openalex.org/W4210750707","https://openalex.org/W4385702585"],"abstract_inverted_index":{"Mantle":[0],"cell":[1],"lymphoma":[2],"(MCL)":[3],"outcomes":[4],"have":[5],"improved":[6],"over":[7],"the":[8,96,116,142,161],"last":[9],"two":[10],"decades;":[11],"however,":[12],"late":[13,57],"relapses":[14],"occur.":[15],"Bortezomib":[16,92],"has":[17,28],"shown":[18],"single":[19],"agent":[20],"activity":[21],"of":[22,48,61,103,124,132,141],"33%":[23],"in":[24,32,121,130],"relapsed":[25],"MCL":[26,78],"and":[27,67,110,112,127,149,182],"an":[29],"additive/synergistic":[30],"effect":[31],"vitro":[33],"when":[34,63],"combined":[35,64,179],"with":[36,50,65,75,81,89,156,180],"drugs":[37],"currently":[38],"used":[39],"to":[40,95,115],"treat":[41],"MCL.":[42],"We":[43],"hypothesized":[44],"that":[45,154,174],"a":[46,100,157],"combination":[47,98],"bortezomib":[49,62,175],"current":[51],"intense":[52],"non-transplant":[53],"chemoimmunotherapy":[54],"might":[55],"prevent":[56],"relapses.":[58],"The":[59,144],"toxicity":[60,140,146],"methotrexate":[66],"cytarabine":[68],"is":[69],"unknown.":[70],"Patients":[71],"aged":[72],"18-79":[73],"years":[74],"untreated":[76],"aggressive":[77],"were":[79,137],"treated":[80],"R-HyperCVAD":[82,181],"(rituximab,":[83],"cyclophosphamide,":[84],"vincristine,":[85],"doxorubicin,":[86],"dexamethasone)":[87],"alternating":[88],"rituximab-methotrexate/cytarabine":[90],"(R-M/A).":[91],"was":[93,113,147,166],"added":[94,114],"R-Hyper-CVAD":[97],"as":[99],"fixed":[101],"dose":[102],"1\u00b73":[104,128],"mg/m(2)":[105,129],"IV":[106],"on":[107],"days":[108],"2":[109],"5":[111],"R-M/A":[117],"regimen":[118,159],"after":[119],"rituximab,":[120],"increasing":[122],"doses":[123],"0\u00b77,":[125],"1,":[126],"cohorts":[131],"three":[133],"patients.":[134],"Twenty":[135],"patients":[136],"assessed":[138],"for":[139],"regimen.":[143],"principal":[145],"haematological":[148],"did":[150],"not":[151],"differ":[152],"from":[153],"observed":[155],"similar":[158],"without":[160],"bortezomib.":[162],"In":[163],"particular,":[164],"there":[165],"no":[167],"pulmonary":[168],"or":[169],"neurological":[170],"dose-limiting":[171],"toxicity,":[172],"showing":[173],"can":[176],"be":[177],"safely":[178],"R-M/A.":[183]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":9},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":10},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":8}],"updated_date":"2026-10-07T09:51:55.459714","created_date":"2016-06-24T00:00:00"}